Inhibitor of cysteine protease

Inhibitor of cholinesterase activity, β-amyloid aggregation and Ca overload; Novel multi-target-directed ligand (MTDL); Activator of kinase 1 and 2 (ERK1/2) and Akt/protein kinase B (PKB) pathways

NRAS inhibitor, targeting the post-translational S-palmitoyl modification of NRAS, causing a dose-dependent decrease in NRAS palmitoylation and inhibiting downstream signaling in melanoma cells with an activating mutation in NRAS

Inhibitor of Pentaglycine Interpeptide Bridge Synthesis

Novel potent tri-vector cyclophilin inhibitor

Novel non-peptidic inhibitor of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction

Novel CypD inhibitor, binding strongly to CypD and attenuating mitochondrial and cellular perturbation insulted by Aß and calcium stress

Novel fungal lanosterol 14α-demethylase (CYP51)/histone deacetylase dual inhibitor, blocking ergosterol biosynthesis and HDAC catalytic activity in fungus, suppressing the function of efflux pump, yeast-to-hypha morphological transition, and biofilm forma

Novel covalent allosteric CYP3A4-effector

Novel potent and selective CYP1A1 inhibitor, antagonizing B[a]P mediated activation of aromatic hydrocarbon receptor (AhR) in yeast cells, and protecting human cells from CYP1A1-mediated B[a]P toxicity in human cells

Potent and selective human CYP11B1 inhibitor

Novel short-acting KOR antagonist

Novel non-peptidic NPBWR1 (GPR7) antagonist

Novel S1PR4 antagonist

Cyclic alkylaminoluciferin substrate for firefly luciferase

Non-peptidic, potent, and orally active stromelysin inhibitor;

Cyclic alkylaminoluciferin substrate for firefly luciferase, emitting 4.7-fold more light than aminoluciferin, and 2.6-fold more light than D-luciferin

immunosuppressive agent

Macrocyclic immunosuppressive peptide, exhibiting a higher plasma concentration than Cyclophilin A

Immunosuppressant

Immunosuppressant

Novel Cyclic Peptide Inhibitor of the p6/UEV Protein-Protein Interaction, disrupting the p6/UEV interaction with an IC50 of 6.17 ± 0.24 μM by binding to UEV with a Kd of 11.9 ± 2.8 μM.

Novel bicyclic peptidyl pan-Ras inhibitor, binding selectively to the GTP-bound forms of wild-type and mutant Ras isoforms (K D = 21 nM for KRasG12V-GppNHp) and being highly cell-permeable and metabolically stable (serum t1/2 > 24 h)

Natural irreversible inhibitor of acetylcholinesterase (AChE)

Novel PD-1/PD-L1 inhibitor, binding two PD-L1 and efficiently block the PD-1/PD-L1 interaction

Natural antibacterial peptide, activating the AAA+ protease ClpC/ClpP, causing cell death by uncontrolled protein degradation

Novel Effective Aminoluciferin Derivative for Deep Bioluminescence Imaging

Androgen receptor (AR) antagonist, inhibiting AR function in castrate-resistant prostate cancer (CRPC)

Novel ABA receptor agonist, preferentially activating Pyrabactin Resistance 1 (PYR1) with low nanomolar potency

Selective D1 agonist with anti-Parkinsonian activity